CHRONIC PAIN & NEUROMODULATION PATHWAY
Prepare a complex chronic pain case for international specialist review—including spinal cord stimulation (SCS), dorsal root ganglion (DRG) stimulation, persistent spinal pain after surgery, CRPS, or an existing device problem.
Initial administrative response normally within two business days. Specialist acceptance and appointment timing depend on documentation, clinical urgency and provider availability.
Case matching across an international provider network, based on clinical fit and availability.
Structured second-opinion preparation for SCS, DRG and other advanced pain pathways.
Provider communication, scheduling and admission support when treatment abroad is appropriate.
Support for discharge communication, programming access, rehabilitation and local handover.
Chronic pain is not a single diagnosis, and persistent pain alone does not establish suitability for an implanted therapy. Before spinal cord stimulation, dorsal root ganglion stimulation, peripheral nerve stimulation, intrathecal therapy, revision, or another advanced pathway is considered, the specialist team needs a clear account of the pain mechanism, anatomical distribution, functional impact, previous treatment, remaining structural questions, medical risks, expectations, and long-term follow-up options.
Healwise helps international patients, families and referring physicians turn fragmented records into a review-ready case. We organize the pain history, body map, imaging and DICOM files, operative reports, medication and intervention timeline, rehabilitation records, available psychological or behavioural assessments, prior trial or implant data, functional goals, and the questions that need specialist review.
We then coordinate review with an appropriate pain medicine, functional neurosurgery, spine, rehabilitation or multidisciplinary team within our international provider network, subject to clinical fit and provider availability. If consultation or treatment abroad is appropriate, Healwise can support appointment scheduling, provider communication, admission preparation, practical travel planning and follow-up handover.
The purpose is not to move every patient toward an implant. Specialist review may support SCS or DRG assessment, request further diagnostics, identify another treatment pathway, or conclude that an implant is not appropriate.
New or rapidly changing symptoms may require local urgent assessment before international coordination is appropriate.
In urgent or unstable situations, contact local emergency or treating medical services first. This website and the Healwise intake route are not emergency services.
Share the information currently available. The file does not need to be complete before you contact us.
We review whether the available records are sufficient for meaningful specialist assessment and identify missing reports, imaging or device information.
We prepare a concise case summary and coordinate the appropriate pain, functional neurosurgery, spine or multidisciplinary review pathway.
Where a provider accepts the case, we support consultation scheduling, further diagnostics, treatment planning, admission, travel-related coordination and follow-up handover.
Initial administrative response: normally within two business days. This is not a guarantee of clinical review, candidacy or appointment timing.
A strong review file should show not only where the pain is, but how it developed, what has already been tried, what remains uncertain, what the patient hopes to improve, and how long-term device care would be organized.
A structured process connects the initial question to appropriate specialist assessment, treatment planning and continuity of care.
Chronic pain may be primary, where no underlying condition adequately explains the pain or its impact, secondary to a defined condition, or a combination of both. This distinction matters because treatment directed at a structural disease, a multidisciplinary pain programme, and an implanted neuromodulation pathway are not interchangeable. A negative test does not make the pain unreal, but it can change which pathway is appropriate.
Specialist review usually considers whether the pattern is predominantly neuropathic, nociceptive, nociplastic, visceral, cancer-related, or mixed. SCS and DRG stimulation are not general solutions for every persistent pain state. The diagnosis, distribution, examination, imaging, and functional effect should support the therapy under discussion.
New compression, instability, infection, tumour, fracture, inflammatory disease, vascular pathology, peripheral nerve entrapment, or another remediable cause may require its own treatment pathway before neuromodulation. Implant review should not replace appropriate diagnostic reassessment when symptoms change.
“Everything has failed” is rarely sufficient for specialist review. The team usually needs to know whether each medication, rehabilitation programme, injection, block, surgery, or psychological intervention was appropriate, completed, tolerated, and assessed against meaningful goals. Short-lived or partial benefit may still provide diagnostic information.
SCS may be discussed for selected adults with chronic neuropathic pain that remains significant despite appropriate conventional management. Suitability depends on diagnosis, pain distribution, previous treatment, medical and psychological assessment, patient goals, technical feasibility, trial response, and access to ongoing support. Persistent pain alone is not an indication.
DRG stimulation may be considered in selected focal neuropathic pain or CRPS-type presentations, particularly when a circumscribed painful area is difficult to target with conventional SCS. Device indications, evidence, reimbursement, and regulatory approval vary by country. Specialist assessment must distinguish CRPS, causalgia or focal nerve pain from widespread or poorly localized pain.
Selected patients may be considered for peripheral nerve stimulation, intrathecal drug delivery, targeted nerve procedures, rehabilitation-focused care, cancer pain pathways, or other specialist approaches. These therapies have different indications, risks, maintenance requirements, and evidence bases and should not be grouped together as equivalent “advanced pain treatments.”
A temporary stimulation trial may help estimate whether a permanent device could provide meaningful benefit. The team should define success criteria in advance, considering pain, function, sleep, activity, medication use, adverse effects, and patient priorities. Trial placement still carries procedural risks, and a positive trial does not guarantee the same degree or durability of long-term benefit.
Permanent implantation requires wound care, activation and programming, repeated optimization, charging or battery management, activity restrictions, MRI and future-procedure planning, and access to revision or explant services. Infection, bleeding, neurological injury, lead migration or fracture, uncomfortable stimulation, generator-site pain, loss of effect, and hardware failure must be discussed by the treating team.
Loss of benefit does not automatically mean that the device should be removed or replaced. Review may need to distinguish disease progression, new pathology, lead migration, programming issues, battery depletion, scar tissue, infection, hardware failure, changed pain distribution, or unrealistic initial expectations. Reprogramming, imaging, revision, replacement, alternative therapy, or explant may each be considered.
The right next step depends on pain mechanism, anatomy, previous treatment, functional goals, medical and psychological readiness, technical feasibility, and the ability to support the patient after treatment.
Some patients need updated imaging, diagnosis clarification, rehabilitation, psychological support, medication review, a pain management programme, treatment of an underlying condition, or a different specialist referral before an implant should be considered.
Selected patients may be assessed for SCS, DRG stimulation, peripheral nerve stimulation, or another device pathway. Assessment includes diagnosis, prior care, goals, risk, trial strategy, technical planning, informed consent, and long-term support.
Patients with an existing stimulator or pump may need programming, generator replacement, imaging review, revision, infection assessment, loss-of-efficacy review, explant discussion, rehabilitation, or transfer of care to a compatible local team.
Implantation is not the end of the pathway. Benefit, safety, function, and device performance need to be reviewed over time.
Speed comes from preparation and coordination. Healwise normally aims to provide an initial administrative response within two business days, but clinical review, acceptance and appointment timing depend on documentation, urgency and specialist availability.
The value of Healwise is structured case preparation and coordination: helping the right information reach the right multidisciplinary team and supporting continuity across assessment, treatment and follow-up.
Practical answers about chronic pain second opinions, SCS and DRG review, international appointments and case submission.
No. Candidacy is determined by a licensed specialist team after reviewing the diagnosis, pain distribution, imaging, previous treatment, medical and psychological readiness, goals, technical feasibility and long-term follow-up options. Healwise prepares the case and coordinates that review.
Yes. This pathway is designed for patients and referring physicians who want a structured second opinion before trial stimulation, permanent implantation, revision, replacement or explantation. The review may also identify missing diagnostics or a more appropriate non-implant pathway.
Potentially. Useful records include the implant make and model, lead location, operative note, programming reports, prior benefit, the timing and pattern of loss of effect, new imaging, current symptoms and any infection or hardware concerns. The receiving team decides whether reprogramming, imaging, revision, replacement, another therapy or explant discussion is appropriate.
Healwise normally aims to provide an initial administrative response within two business days. The timing of specialist review or an appointment depends on documentation completeness, clinical urgency, provider acceptance and availability. No consultation or treatment date is guaranteed before the receiving provider accepts the case.
No. Submit the information currently available and explain the main question. Healwise can identify which reports, imaging, pain history, treatment records or device information are still needed before meaningful specialist review.
Where treatment abroad is clinically appropriate and a provider accepts the case, Healwise can support appointment scheduling, provider communication, admission preparation, translation, practical travel planning, cost-process clarity, discharge communication and follow-up handover. Clinical recommendations and treatment are provided by licensed healthcare professionals.
If you are a patient, family member or referring physician managing a complex chronic pain, SCS, DRG stimulation or device-related question, submit the information currently available. Healwise will review the file for fit and completeness and explain the next coordination step.
Initial administrative response normally within two business days.
Structured neurosurgical case coordination for international patients, families and referring physicians.
Healwise International Ltd.
Budapest, Hungary
